

17TH ANNUAL CONFERENCE OF THE
BRITISH HIV ASSOCIATION (BHIVA)

British HIV Association
BHIVA

Dr Neesha Rockwood
Chelsea and Westminster Hospital, London

6-8 April 2011, Bournemouth International Centre

SSAT
ST STEPHEN'S AIDS TRUST


**A comparative analysis of risk factors
associated with efavirenz, atazanavir/r,
darunavir/r, lopinavir/r, and renal
impairment**

**N Rockwood, S Mandalia, J Sirokosta, R Jones, M
Boffito, M Bower, B Gazzard, M Nelson**

Chelsea and Westminster Hospital **NHS**
NHS Foundation Trust


Background (1)


Risk factors for renal disease



Background (2)

Areas for potential reduction of renal disease





- To compare the association of EFV, ATZ/r, DRV/r & LPV/r with renal impairment which we defined as **reaching first eGFR<60 ml/min per 1.73m²** in individuals commencing these therapies with a baseline eGFR above this threshold
- To assess renal recovery over time post first eGFR<60 ml/min per 1.73m²

* eGFR: estimated glomerular filtration rate



Methods

- Retrospective cohort study: June '06 – Feb '10
- Inclusion criteria:
 - Patients commencing on or switching to HAART containing:
 1. 2NRTI+ EFV
 2. 2NRTI+ ATZ/r
 3. 2NRTI+ DRV/r
 4. 2NRTI+ LPV/r
 - Available baseline eGFR >60 ml/min per 1.73m²
- Event was censored at:
 - eGFR<60 ml/min per 1.73m²
 - stopping study combination
 - death
 - end of study period

Chelsea and Westminster Hospital 
NHS Foundation Trust



Statistical analysis

- Cox's proportional hazards regression model (univariate and multivariate analysis): to show likelihood of renal impairment (eGFR<60 ml/min per 1.73m²)
- Mixed procedure in SAS: estimation of proportion renal recovery with time

Chelsea and Westminster Hospital 
NHS Foundation Trust

Results (1)

386 (18%) developed renal impairment during study

Baseline demographics	Overall cohort n= 2115
Gender: n (%)	
Male	1842 (87%)
Female	273 (13%)
Ethnicity	
Caucasian	1520 (72%)
Black African	259 (12%)
Other	313 (15%)
Unknown	23 (1%)
Age (yrs) : mean (SD)	43 (9.5)
Median baseline CD4 (cells/mm³)	383
% with undetectable VL at baseline (<50copies/ml)	60

Results (2) univariate analysis

Significant associations with eGFR<60 ml/min per 1.73m²

	Hazard Ratio (95% CI)		P value
Gender			
F	1.5	(1.16-1.96)	0.002
M	1		
Baseline age (yrs)			
<35	1		
36-43	1.3	(0.92-1.82)	<0.001
43-48	2	(1.5-2.82)	
>48	2.8	(2.03-3.73)	
Baseline eGFR			
<69	12.8	(8.5-19.2)	<0.001
69-78	2.4	(1.6-3.8)	
79-84	1.4	(0.8-2.3)	
>84	1		

Results (3) univariate analysis

Significant associations with eGFR<60 ml/min per 1.73m²

	Hazard Ratio (95% CI)		P value
Hep S Ag +ve status	1.21	(0.59-1.63)	<0.001
Previous IND exposure	2.03	(1.58-2.62)	<0.001
Previous TFV exposure	1.68	(1.38-2.05)	<0.001
Tot duration TFV exposure	1.09	(1.06-1.12)	<0.001
ATZ/r exposure	1.27	(1.02-1.58)	<0.036
DRV/r exposure	1.53	(1.22-1.92)	<0.001
LPV/r exposure	1.71	(1.38-2.24)	<0.001
EFV exposure	0.6	(0.47-0.73)	<0.001

Results (4) traditional risk factors

Traditional risk factor	EFV group n=50	PI group n=110	P value
Diabetes n (%)	10 (20)	14 (12.8)	0.34
Hypertension n (%)	16 (32)	22 (20)	0.15
Renal stones n (%)	0 (0)	7 (6.4)	0.16
Cardiovascular disease n (%)	2 (4)	11 (10)	0.33
Peripheral vascular disease n (%)	3 (6)	6 (5.5)	0.82
Nephrotoxic drugs n (%)	22 (44)	45 (40.9)	0.84
Chemotherapy n(%)	1 (2)	14 (12.7)	0.06
Sepsis n (%)	0 (0)	6 (5.45)	0.22

160 patients randomly selected out of 386 who developed renal impairment



Results (5) multivariate analysis


	†Hazard Ratio	(95% CI)	P value
LPV/r	1.69	(1.1-2.6)	0.017
ATZ/r	1.52	(1.14-2.03)	0.004
DRV/r	1.31	(0.94-1.81)	0.108
EFV	1		


†Adjusted for gender, age at start of HAART, baseline eGFR, Hep B SAg, prior exposure to TFV and IND and total duration of TFV exposure



Results (6) renal recovery

% renal recovery with time post first eGFR <60 ml/min per 1.73m²





SSAT ST STEPHEN'S AIDS TRUST **Conclusions**

- 386 (18%) reached eGFR < 60 ml/min per 1.73m² during study
- There was a significant risk of renal impairment with boosted ATZ and LPV
- Post first eGFR < 60 ml/min per 1.73m², at 12 months, 50% of patients had renal recovery but this decreased with further length of follow up. Also the longitudinal increment in eGFR was not sustained.

Chelsea and Westminster Hospital NHS Foundation Trust



Acknowledgements

Mark Nelson

Brian Gazzard

Sundhiya Mandalia

Emma Page

Michael Rayment

Chelsea and Westminster Hospital 
NHS Foundation Trust



Conclusions

- 386 (18%) reached $eGFR < 60 \text{ ml/min per } 1.73 \text{ m}^2$ during study
- There was a significant risk of renal impairment with boosted ATZ and LPV
- Post first $eGFR < 60 \text{ ml/min per } 1.73 \text{ m}^2$, at 12 months, 50% of patients had renal recovery but this decreased with further length of follow up. Also the longitudinal increment in $eGFR$ was not sustained.

Chelsea and Westminster Hospital 
NHS Foundation Trust